Zykadia (ceritinib) / Novartis 
Welcome,         Profile    Billing    Logout  
 20 Diseases   19 Trials   19 Trials   1652 News 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT02584933 / 2015-001922-40: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Active, not recruiting
4
233
Europe, Japan, US, RoW
ceritinib
Novartis Pharmaceuticals
ALK Positive Malignancies
06/25
06/25
NCT01828112 / 2012-005637-36: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Completed
3
231
Europe, Canada, Japan, US, RoW
Ceritinib, pemetrexed, docetaxel
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
01/16
11/23
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
2019-001828-36: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Not yet recruiting
2
116
Europe
Brigatinib, Alecensa, Zykadia, Film-coated tablet, Capsule, hard, Alunbrig
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Takeda Pharmaceutical Company Ltd
Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC), Non-small cell lung cancer, Diseases [C] - Cancer [C04]
 
 
ALTA-2, NCT03535740: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Active, not recruiting
2
103
Europe, Canada, Japan, US, RoW
Brigatinib, AP26113
Ariad Pharmaceuticals, Takeda
ALK-positive Advanced NSCLC
09/20
06/24
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
NCT03501368: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Active, not recruiting
1
27
US
Ceritinib, ZYKADIA, Trametinib, MEKINIST
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Melanoma, Unresectable Melanoma, Advanced Melanoma
10/22
08/24
NCT02393625: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
1
57
Europe, Canada, US, RoW
Ceritinib (LDK378), Nivolumab
Novartis Pharmaceuticals
ALK-positive NSCLC
04/25
04/25
NCT01947608: Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

No Longer Available
N/A
US, RoW
LDK378
Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
 
 
NCT05100134: Managed Access Programs for LDK378, Ceritinib

Available
N/A
NA
ceritinib, LDK378
Novartis Pharmaceuticals
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
 
 
NCT03546894: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed
N/A
111
US
Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors
Takeda
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
02/23
02/23
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Recruiting
N/A
20605
Europe
lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib
Pfizer
Non-Small Cell Lung Cancer
02/25
02/25

Download Options